Kemnay Advisory Services Inc. lowered its stake in Humana Inc (NYSE:HUM) by 10.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,855 shares of the insurance provider’s stock after selling 433 shares during the period. Kemnay Advisory Services Inc.’s holdings in Humana were worth $1,305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of the business. FMR LLC raised its position in Humana by 1.4% in the 3rd quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock valued at $4,190,809,000 after purchasing an additional 167,283 shares in the last quarter. BlackRock Inc. raised its position in Humana by 1.2% in the 3rd quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock valued at $4,167,767,000 after purchasing an additional 140,731 shares in the last quarter. Renaissance Technologies LLC raised its position in Humana by 14.1% in the 3rd quarter. Renaissance Technologies LLC now owns 3,174,800 shares of the insurance provider’s stock valued at $1,074,733,000 after purchasing an additional 391,300 shares in the last quarter. Northern Trust Corp raised its position in Humana by 1.2% in the 2nd quarter. Northern Trust Corp now owns 1,687,211 shares of the insurance provider’s stock valued at $502,164,000 after purchasing an additional 20,480 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Humana by 4.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 804,090 shares of the insurance provider’s stock valued at $272,199,000 after purchasing an additional 35,845 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors.
HUM has been the topic of a number of analyst reports. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $377.00 price target on the stock in a research report on Thursday, October 4th. Argus increased their price target on Humana to $375.00 and gave the company a “buy” rating in a research report on Tuesday, September 4th. Morgan Stanley increased their price target on Humana from $400.00 to $418.00 and gave the company a “buy” rating in a research report on Thursday, November 8th. BMO Capital Markets set a $390.00 price target on Humana and gave the company a “buy” rating in a research report on Thursday, November 8th. Finally, Bank of America increased their price target on Humana from $400.00 to $415.00 and gave the company a “buy” rating in a research report on Thursday, November 8th. Seven research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $352.30.
Shares of NYSE HUM opened at $324.47 on Thursday. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.45. Humana Inc has a fifty-two week low of $242.00 and a fifty-two week high of $355.88. The stock has a market cap of $44.51 billion, a PE ratio of 27.71, a price-to-earnings-growth ratio of 1.54 and a beta of 0.99.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, topping the consensus estimate of $4.29 by $0.29. Humana had a return on equity of 19.10% and a net margin of 2.70%. The business had revenue of $14.21 billion for the quarter, compared to analyst estimates of $13.97 billion. During the same quarter last year, the company earned $3.39 EPS. Equities analysts forecast that Humana Inc will post 14.43 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Stockholders of record on Monday, December 31st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 0.62%. The ex-dividend date of this dividend is Friday, December 28th. Humana’s dividend payout ratio (DPR) is presently 11.96%.
In related news, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the transaction, the chief executive officer now owns 71,085 shares in the company, valued at approximately $23,362,796.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Roy A. Beveridge sold 4,622 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $341.06, for a total value of $1,576,379.32. Following the transaction, the insider now owns 10,621 shares in the company, valued at approximately $3,622,398.26. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Kemnay Advisory Services Inc. Has $1.31 Million Holdings in Humana Inc (HUM)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/06/kemnay-advisory-services-inc-has-1-31-million-holdings-in-humana-inc-hum.html.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Read More: Can individual investors take part in an IPO?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.